QUILT-3.092 trial: what clinicians have said so far
Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma
- NCT05618925 ↗
- Recruiting
- ImmunityBio, Inc.
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on QUILT-3.092 (CD19 t-haNK plus rituximab; CD19 t-haNK plus nogapendekin alfa inbakicept (N-803) plus rituximab in relapsed/refractory non-Hodgkin lymphoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on QUILT-3.092 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- Open-label, Phase 1 Study of CD19 t-haNK as a Single Agent and in Combination With an IL-15 Superagonist (N-803) and Rituximab in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma.
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Non Hodgkin's Lymphoma Refractory/Relapsed
- Interventions
- N803; CD19t-haNK suspension; Cyclophosphamide; Fludarabine; Rituximab
- Arms
- Arm A · Experimental
- Arm B · Experimental
- Enrollment
- 20 (estimated)
- Primary outcomes
- Primary Outcome Measures
- Sponsor
- ImmunityBio, Inc.
- Start
- Aug 22, 2025
- Primary completion
- May 15, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT05618925 · updated Apr 1, 2026